<DOC>
	<DOCNO>NCT00240578</DOCNO>
	<brief_summary>This multi-center study long-term follow-up surviving patient expect complete complete least two year follow-up treatment Iodine I 131 Tositumomab ( BEXXAR ) Studies CP-97-011 , CP-98-025 , CP-99-032 , CP-99-036 . All patient assess survival disease status , include subsequent therapy NHL , long-term safety . Additionally Laboratory evaluation consist TSH level complete blood cell ( CBC ) count differential platelet count obtain annually . Additionally , patient remain long-term response follow Iodine I 131 Tositumomab treatment follow response progression .</brief_summary>
	<brief_title>Patients With Low-Grade Non-Hodgkin 's Lymphoma Previously Treated With Iodine I 131 Tositumomab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients must enrol one follow Corixa sponsor clinical trial : CP97011 , CP98025 , CP99032 , CP99036 &gt; 2 year post treatment Iodine I 131 Tositumomab . Patients must give write informed consent sign IRB/ethics committee approve consent form prior entry followup study . Inability meet reference inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Long-Term Follow-up</keyword>
	<keyword>BEXXAR</keyword>
	<keyword>Iodine I 131 Tositumomab</keyword>
	<keyword>Low-grade lymphoma</keyword>
</DOC>